ISSN: 2278-0238

Revue internationale de recherche et développement en pharmacie et sciences de la vie

Accès libre

Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.

Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs

Abstrait

ICUed COVID-19 Patients with Hepatic Problems during the Third Wave of Coronavirus in Egypt

Alzhraa M. Fahmy, Marwa O. Elgendy, Ahmed M. Khalaf, Mona A. Abdelrahman, Ahmed O. El-Gendy

<p><strong>Background: </strong>The pandemic infection of COVID-19 virus is mostly a respiratory infection that has recently begun
to harm other vital organs, including the heart, kidney and liver.</p>
<p>Aim of work: The purpose of this study was to investigate the hepatic complications of COVID-19 patients and the
risks of being admitted to the ICU or dying.</p>
<p><strong>Methodology: </strong>The study included 200 COVID-19 infected Egyptian individuals who had virological symptoms and were tracked until they recovered or died; classified into six parts: co-morbidities (hypertension &amp; diabetes), experienced symptoms of COVID-19, laboratory findings (ALT enzyme level, AST enzyme level, Albumin), complications during
hospitalization, treatment protocol used and the survival outcomes.</p>
<p><strong>Results and Conclusion:</strong> It was recorded that older people and those with higher blood sugar levels have a higher risk of developing liver-associated COVID-19 disorders. Also, the majority of individuals who developed liver complications in the course of the infection experienced a high mortality rate. Patients with diabetes, hypertension or hepatic disease are at high risk to be admitted into ICU or to die. So, it is important to pay attention to these problems in the diagnosis and treatment of COVID-19 to develop a suitable individualized treatment protocol. There was a correlation between mortality in COVID 19 patients and both high blood sugar levels and high liver enzymes levels. It can be attributed to the diabetes and liver disease correlation as every disease may be the complication to the other, also, COVID 19 can lead to blood sugar level rise in addition to liver enzymes (ALT-AST) levels. Also, there was
another suggestion that COVID19 may affect liver and so the chronic liver disease patients.</p>